A
Aculys Pharma
Committed to the patient experience including the awareness, screening, diagnosis, treatment of disease and the resolution of surrounding social issues for patients and their families confronted…
About Aculys Pharma
Aculys is a forward-thinking startup focused on revolutionizing the treatment of sleep-related diseases. The company operates in the healthcare and pharmaceutical sector, specifically targeting nervous and mental health conditions. Aculys is dedicated to developing new drugs that offer innovative treatment options for sleep disorders, which are known to significantly impact both individual health and the broader economy. For instance, sleep-related diseases contribute to an economic loss of about 2.9% of Japan's gross national product.
Aculys serves a diverse range of clients, including patients suffering from sleep disorders, their families, healthcare professionals, and medical institutions. The company aims to improve cognitive awareness about these conditions, ensuring that more patients receive accurate diagnoses and effective treatments.
The business model of Aculys revolves around clinical drug development. This involves extensive research and testing to create new medications that can be brought to market. The company collaborates with various stakeholders, such as patients, families, medical conferences, and healthcare personnel, to enhance the understanding and management of sleep-related diseases.
Aculys generates revenue primarily through the sale of its newly developed drugs once they receive regulatory approval. Additionally, the company may engage in partnerships or licensing agreements with other pharmaceutical firms to expand the reach of its treatments.
In summary, Aculys is committed to transforming the landscape of sleep disorder treatment through innovative drug development, aiming to improve patient outcomes and reduce the economic burden of these conditions.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2021
- Headquarters
- Fujisawa, Japan
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 61.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Oct 2025 | $0 | — | Viatris | ↗ |
| SERIES BOther financing | Mar 2022 | $22M | $86M | HBM Partners · ANRI · Spiral Capital · Mitsubishi UFJ Capital | ↗ |
Growth signals
Latest recorded traffic for Aculys Pharma is 2.3K monthly website visits, down 50% over the last three months. Aculys Pharma's team declined 43.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
SoftBank
HBM Partners
ANRI
Spiral Capital
Mitsubishi UFJ Capital
Sumitomo Mitsui Trust Investment
Catalys Pacific
JIC Venture Growth Investments
HBM Healthcare Investments
Other known investors1 additional known investor
Viatris
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aculys Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aculys Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







